A medical expert navigates the treatment landscape for patients newly diagnosed with multiple myeloma.
This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.
When asked what the ideal patient is for the 4-drug combination of lenalidomide, bortezomib, and dexamethasone plus daratumumab, Fonseca responded that is the wrong question; rather, clinicians should consider if there are any patients who should not receive this regimen.
Minimal residual disease (MRD) testing has become central to myeloma treatment goals. As the most sensitive test for residual disease, MRD negativity is now the most important prognostic factor in myeloma. Four analyses support the predictive value of MRD status. Unknowns remain regarding discontinuing therapy with sustained MRD negativity and escalating therapy for persistent MRD positivity, although Fonseca tests patients routinely after transplant to guide next treatment steps aimed at achieving MRD negativity. While this must be done judiciously, he believes eliminating every myeloma cell should be the primary goal.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen